Ausgabe 3/2017
Inhalt (27 Artikel)
Immunoglobulin-like domain 4-mediated ligand-independent dimerization triggers VEGFR-2 activation in HUVECs and VEGFR2-positive breast cancer cells
Sheng Zhang, Xiaoping Gao, Wei Fu, Shengwei Li, Limin Yue
Metformin sensitizes triple-negative breast cancer to proapoptotic TRAIL receptor agonists by suppressing XIAP expression
Elena Strekalova, Dmitry Malin, Harisha Rajanala, Vincent L. Cryns
A83-01 inhibits TGF-β-induced upregulation of Wnt3 and epithelial to mesenchymal transition in HER2-overexpressing breast cancer cells
Yanyuan Wu, Trinh Tran, Sami Dwabe, Marianna Sarkissyan, Juri Kim, Miguel Nava, Sheilah Clayton, Richard Pietras, Robin Farias-Eisner, Jaydutt V. Vadgama
Tumour suppressor EP300, a modulator of paclitaxel resistance and stemness, is downregulated in metaplastic breast cancer
Muhammad Asaduzzaman, Stephanie Constantinou, Haoxiang Min, John Gallon, Meng-Lay Lin, Poonam Singh, Selina Raguz, Simak Ali, Sami Shousha, R. Charles Coombes, Eric W.-F. Lam, Yunhui Hu, Ernesto Yagüe
ΔNp63 activates EGFR signaling to induce loss of adhesion in triple-negative basal-like breast cancer cells
Jitka Holcakova, Marta Nekulova, Paulina Orzol, Rudolf Nenutil, Jan Podhorec, Marek Svoboda, Petra Dvorakova, Mariana Pjechova, Lenka Hernychova, Borivoj Vojtesek, Philip J. Coates
FOXM1 transcriptionally regulates expression of integrin β1 in triple-negative breast cancer
Zuhal Hamurcu, Nermin Kahraman, Ahmed Ashour, Bulent Ozpolat
Efficacy and safety of nab-paclitaxel 125 mg/m2 and nab-paclitaxel 150 mg/m2 compared to paclitaxel in early high-risk breast cancer. Results from the neoadjuvant randomized GeparSepto study (GBG 69)
Jenny Furlanetto, Christian Jackisch, Michael Untch, Andreas Schneeweiss, Sabine Schmatloch, Bahriye Aktas, Carsten Denkert, Hermann Wiebringhaus, Sherko Kümmel, Mathias Warm, Stefan Paepke, Marianne Just, Claus Hanusch, John Hackmann, Jens Uwe Blohmer, Michael Clemens, Serban Dan Costa, Bernd Gerber, Valentina Nekljudova, Sibylle Loibl, Gunter von Minckwitz
Cardiac safety, efficacy, and correlation of serial serum HER2-extracellular domain shed antigen measurement with the outcome of the combined trastuzumab plus CMF in women with HER2-positive metastatic breast cancer: results from the EORTC 10995 phase II study
Konstantinos Tryfonidis, S. Marreaud, H. Khaled, B. De Valk, J. Vermorken, M. Welnicka-Jaskiewicz, K. Aalders, J. M. S. Bartlett, L. Biganzoli, J. Bogaerts, David Cameron
Quality of life in patients with recurrent breast cancer after second breast-conserving therapy in comparison with mastectomy: the German experience
Svenja Jendrian, Katharina Steffens, Barbara Schmalfeldt, Elena Laakmann, Corinna Bergelt, Isabell Witzel
Chemotherapy-induced irreversible alopecia in early breast cancer patients
Gun Min Kim, Sanghwa Kim, Hyung Seok Park, Jee Ye Kim, Sanggen Nam, Seho Park, Seung Il Kim, DoYoung Kim, Joohyuk Sohn
A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer
José Baselga, Serafin M. Morales, Ahmad Awada, Joanne L. Blum, Antoinette R. Tan, Marianne Ewertz, Javier Cortes, Beverly Moy, Kathryn J. Ruddy, Tufia Haddad, Eva M. Ciruelos, Peter Vuylsteke, Scot Ebbinghaus, Ellie Im, Lamar Eaton, Kumudu Pathiraja, Christine Gause, David Mauro, Mary Beth Jones, Hope S. Rugo
Outcomes of fulvestrant therapy among japanese women with advanced breast cancer: a retrospective multicenter cohort study (JBCRG-C06; Safari)
H. Kawaguchi, N. Masuda, T. Nakayama, K. Aogi, K. Anan, Y. Ito, S. Ohtani, N. Sato, S. Saji, E. Tokunaga, S. Nakamura, Y. Hasegawa, M. Hattori, T. Fujisawa, S. Morita, M. Yamaguchi, T. Yamashita, Y. Yamamoto, S. Ohno, M. Toi
Failure patterns according to molecular subtype in patients with invasive breast cancer following postoperative adjuvant radiotherapy: long-term outcomes in contemporary clinical practice
Yu Jin Lim, Sea-Won Lee, Noorie Choi, Jeanny Kwon, Keun-Yong Eom, Eunyoung Kang, Eun-Kyu Kim, Sung-Won Kim, Jee Hyun Kim, Yu Jung Kim, Se Hyun Kim, So Yeon Park, Jae-Sung Kim, In Ah Kim
Breast cancer detection and tumor characteristics in BRCA1 and BRCA2 mutation carriers
Julia Krammer, Katja Pinker-Domenig, Mark E. Robson, Mithat Gönen, Blanca Bernard-Davila, Elizabeth A. Morris, Debra A. Mangino, Maxine S. Jochelson
Background parenchymal enhancement on breast MRI: association with recurrence-free survival in patients with newly diagnosed invasive breast cancer
Yaeji Lim, Eun Sook Ko, Boo-Kyung Han, Eun Young Ko, Ji Soo Choi, Jeong Eon Lee, Se Kyung Lee
Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-world population of hormone receptor-positive (ER+/PgR+), HER2-negative advanced breast cancer (ABC) patients: a multicenter Italian experience
Mariangela Ciccarese, Alessandra Fabi, Luca Moscetti, Maria Elena Cazzaniga, Luciana Petrucelli, Rosachiara Forcignanò, Laura Isabella Lupo, Elisabetta De Matteis, Vincenzo Emanuele Chiuri, Giuseppe Cairo, Antonio Febbraro, Guido Giordano, Marianna Giampaglia, Domenico Bilancia, Nicla La Verde, Evaristo Maiello, Maria Morritti, Francesco Giotta, Vito Lorusso, Agnese Latorre, Claudio Scavelli, Sante Romito, Antonio Cusmai, Gennaro Palmiotti, Giammarco Surico
Self-reported long-term cardiac morbidity in breast cancer patients: a retrospective cohort study in Germany (PASSOS Heart Study)
Daniel Wollschläger, Hiltrud Merzenich, Lukas Schwentner, Wolfgang Janni, Thomas Wiegel, Detlef Bartkowiak, Achim Wöckel, Marcus Schmidt, Heinz Schmidberger, Maria Blettner
Is breast compression associated with breast cancer detection and other early performance measures in a population-based breast cancer screening program?
Nataliia Moshina, Sofie Sebuødegård, Solveig Hofvind
Relationship of breast MRI to recurrence rates in patients undergoing breast-conservation treatment
Maureen V. Hill, Julia L. Beeman, Khushboo Jhala, Stefan D. Holubar, Kari M. Rosenkranz, Richard J. Barth Jr.
Aromatase expression in atypical ductal hyperplasia in women
R. J. Santen, D. C. Radisky, A. Degnim, M. H. Frost, C. M. Vachon, K. Ghosh, F. Guestini, K. M. McNamara, H. Sasano
Ovarian suppression in combination endocrine adjuvant therapy in premenopausal women with early breast cancer
Paola Muti, Giorgio Secreto, Vittorio Krogh
Cost-effectiveness of palbociclib plus letrozole versus letrozole alone as a first-line treatment in women with oestrogen receptor-positive, HER2-negative, advanced breast cancer. Revised results for the Swiss health care setting
K. Matter-Walstra, M. Schwenkglenks, K. J. Dedes
Erratum to: Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2− breast cancer: results from two prospective trials
M. V. Dieci, A. Frassoldati, D. Generali, G. Bisagni, F. Piacentini, L. Cavanna, K. Cagossi, F. Puglisi, A. Michelotti, R. Berardi, G. Banna, A. Goubar, G. Ficarra, G. Griguolo, Pierfranco Conte, V. Guarneri
Erratum to: ESR1 mutations affect anti-proliferative responses to tamoxifen through enhanced cross-talk with IGF signaling
Luca Gelsomino, Guowei Gu, Yassine Rechoum, Amanda R. Beyer, Sasha M. Pejerrey, Anna Tsimelzon, Tao Wang, Kenneth Huffman, Andrew Ludlow, Sebastiano Andò, Suzanne A. W. Fuqua